AZM Alizyme

    RNS Number : 5661K
  Alizyme PLC
  22 December 2008
   

 For Immediate Release  22 December 2008


    ALIZYME plc

    TAKEDA COMMENCE CETILISTAT (ATL-962) PHASE III PROGRAMME IN JAPAN

    Cambridge UK, 22 December 2008: Alizyme plc (LSE:AZM) is pleased to announce that Takeda Pharmaceutical Company Limited ("Takeda") has
commenced a Phase III clinical study in Japan of cetilistat (ATL-962) for the treatment of obesity.


    Takeda, Alizyme's partner for the development and commercialisation of cetilistat in Japan, has today announced the commencement of its
Phase III study for cetilistat in the treatment of obesity in Japan.

    In September 2008, Alizyme announced that it was to receive a milestone payment of US$3 million under the licence and development
agreement between Takeda and Alizyme, following the decision by Takeda to commence Phase III development of cetilistat in Japan. Takeda has
today announced the formal commencement of the study.


    Tim McCarthy, Chief Executive Officer, Alizyme plc, commented:

    "We are delighted with Takeda's rapid progression into their Phase III study for cetilistat. We have an excellent working relationship
with Takeda, developed over the past five years, and we look forward to continuing to work together as cetilistat is progressed through
Phase III development and on to commercialisation in Japan."



    For further information, please contact:

                           Alizyme plc  Tel: + 44 (0) 1223 896000
 Tim McCarthy, Chief Executive Officer

               Buchanan Communications  Tel: + 44 (0) 20 7466 5000
                         Lisa Baderoon
                 Rebecca Skye Dietrich



    Editor's Note

    Alizyme plc

    Alizyme is a speciality biopharmaceutical development company, focused on the therapeutic areas of metabolic disorders, gastrointestinal
disorders and cancer supportive care. It is developing cetilistat for the treatment and management of obesity and associated co*morbidities,
including type 2 diabetes, COLAL*PRED� for ulcerative colitis, and ATL*104 for mucositis, a side effect of cancer therapy.

    Further information on Alizyme can be found on the Company's website: www.alizyme.com


    Takeda Pharmaceutical Company Limited

    Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one
of the industry's leaders worldwide, Takeda is committed to strive toward better health for individuals and progress in medicine by
developing superior pharmaceutical products.

    Further information on Takeda can be found on its corporate website: www.takeda.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCUUUNRWKRUURA

Alizyme (LSE:AZM)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Alizyme (LSE:AZM)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024